Strive (ASST) released third quarter 2026 results that reshaped its recent financial story, reporting US$2.7 million in revenue alongside US$509.03 million in net income from continuing operations.

Strive's recent earnings announcement, impairment on medical device intangibles, and aggressive weekly Bitcoin purchases have landed against a choppy tape, with the share price down 16.1% over the past week and 24.9% over the past month, yet still showing a 22.8% 90 day share price return and a 3 year total shareholder return that has fallen 44.9%. This pattern points to short term momentum fading after a sharp rebound while longer term holders remain deeply under water.

Pressure test Strive's wild mix of Bitcoin exposure and medical device earnings against a curated set of 21 cryptocurrency and blockchain stocks that lean into the same digital asset theme.

Strive trades at a steep discount to analyst targets after a sharp pullback. Yet the mix of medical device impairments and heavy Bitcoin buying raises a simple question: Is this caution mispricing, or basic risk management by the market?

Preferred Price-to-Book of 1.6x: Is it justified?

Strive closed at $18.09 with the market valuing it at a price-to-book ratio of 1.6x, a level that screens as inexpensive when stacked against both peers and the broader US Medical Equipment group.

P/B compares the share price to the accounting value of net assets. For a business like Strive, which blends an asset management arm, a medical device operation and a Bitcoin treasury approach, that measure gives a quick read on how much of a premium or discount investors are paying relative to the book value backing each share.

The stock is flagged as good value against a peer average P/B of 8.7x. That is a wide gap. It indicates that the market is assigning a far lower valuation to Strive's equity base than to similar companies, even though revenue has grown 75.1% over the past year and the firm continues to invest in both medical technology and digital assets. At the same time, the group remains unprofitable with a negative return on equity of 8.15%, carries 100% of its liabilities from higher risk funding sources and has recently diluted shareholders. These factors can all help explain why the market is reluctant to pay a richer multiple.

Compared with the US Medical Equipment industry average P/B of 2.4x, Strive's 1.6x still looks compressed. The discount is smaller than against its direct peer set, yet it points to a market that is more cautious about unprofitable growth, volatile Bitcoin exposure, insider selling over the past three months and a young board and management bench than it is about the sector overall.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 1.6x (UNDERVALUED)

Still, Strive's reliance on a Bitcoin treasury approach and ongoing shareholder dilution through its at the market program could quickly challenge any straightforward undervaluation narrative.

Find out about the key risks to this Strive narrative.

Next Steps

Strive clearly divides opinion, with Bitcoin bets and medical device setbacks pulling sentiment in opposite directions. Move fast, review the underlying metrics, and weigh the 1 key reward and 4 important warning signs for yourself.

Hunting for more ideas beyond Strive?

If Strive's mix of Bitcoin exposure and medical devices feels like only one piece of your portfolio puzzle, you can broaden your opportunity set with a few focused screens.

Skip aimless stock browsing and put a sharpened process to work across other potential opportunities using the Simply Wall Street Screener.

Target underpriced quality by scanning for businesses that pair robust fundamentals with discounted valuations through the 38 high quality undervalued stocks.

Build staying power into your holdings by leaning on the 29 resilient stocks with low risk scores for companies with more resilient risk profiles and fewer financial red flags.

Spot lesser known opportunities before the crowd by running the 18 high quality undiscovered gems and filtering for solid metrics that the market may be overlooking.

This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASST.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]